ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 0631

Clinical Manifestations and Outcomes in DMARD-Naïve Patients with Chronic Chikungunya Arthritis

Nicolle Medina-Cintrón1, Idali Martínez1, Naydi Pérez-Ríos2, Yaritza Berríos-López2 and Luis Vilá3, 1University of Puerto Rico Medical Science Campus, San Juan, Puerto Rico, 2University of Puerto Rico Medical Sciences Campus, San Juan, Puerto Rico, 3University of Puerto Rico Medical Sciences Campus, San Juan

Meeting: ACR Convergence 2020

Keywords: Disability, Infection, Outcome measures

  • Tweet
  • Email
  • Print
Session Information

Date: Saturday, November 7, 2020

Title: Infection-related Rheumatic Disease Poster

Session Type: Poster Session B

Session Time: 9:00AM-11:00AM

Background/Purpose: Chikungunya virus (CHIKV) is characterized by fever, maculopapular rash, and severe polyarthralgia and polyarthritis.  Up to 80% of affected individuals may develop chronic CHIKV arthralgias and arthritis.  Most studies on chronic CHIKV arthritis include patients treated with disease-modifying anti-rheumatic drugs (DMARDs), most likely altering the expression of clinical manifestations during the chronic phase.  Therefore, we sought to evaluate the clinical features and correlates in patients with chronic CHIKV arthritis who did not receive therapy with DMARDs.

Methods: We conducted a cross-sectional study in adult (≥21 years) patients with serologically-confirmed CHIKV infection in Puerto Rico.  All patients had inflammatory polyarthritis in the acute phase of infection.  None received treatment with corticosteroids one year before study visit and, none receive DMARDs at any time.  Demographic features, lifestyle behaviors, clinical manifestations, comorbidities, disease activity (per Clinical Disease Activity Index [CDAI]), functional status (per Health Assessment Questionnaire [HAQ]), and pharmacologic treatment were ascertained.  Patients with and without chronic CHIKV arthritis were compared.  Furthermore, a sub-analysis was performed among patients with chronic CHIKV who presented with low disease activity (CDAI < 10) versus moderate-high disease activity (CDAI ­­≥ 10) at study visit.  Statistical analyses were performed using Fisher’s exact test, Pearson Chi-squared test, and Wilcoxon rank-sum test, as appropriate.

Results: In total, 61 patients were studied; 41 (67.2%) were women and the mean (standard deviation [SD]) period between onset of CHIKV infection and study visit was 23.4 (9.4) months.  Thirty-three patients had chronic arthritis and 28 had resolved arthritis.  Patients with chronic arthritis were more likely to have diabetes mellitus, chronic back pain, other symptoms on the acute phase (fever, tiredness, and myalgia), and to receive treatment with NSAIDs on the acute phase (Table 1).  Among patients with chronic CHIKV arthritis, joint tenderness was most common in MCP joints (54.6%), shoulders (51.5%), PIP joints (45.5%), and knees (39.4%) at study visit.  Swelling was observed in PIP joints (15.2%), MCP joints (12.1%), shoulders (9.1%), wrists (6.1%), ankles (6.1%), and MTP joints (3.0%).  The mean (SD) HAQ score was 0.95 (0.56) and 57.6% had moderate-high disease activity per CDAI.  Patients with moderate-high disease activity were more likely to have higher scores in overall HAQ and HAQ categories (dressing & grooming, arising, hygiene, reaching, and activities) when compared to those with mild activity (Table2).

Conclusion: In this group of DMARD-naïve patients with chronic CHIKV arthritis, nearly 58% had moderate to severe disease activity.  Those patients had major functional disability, including significant dysfunction in several HAQ categories.  Diabetes mellitus, chronic low back pain, and some manifestations on acute infection (fever, tiredness, and myalgias) were associated with chronic CHIKV arthritis.


Disclosure: N. Medina-Cintrón, None; I. Martínez, None; N. Pérez-Ríos, None; Y. Berríos-López, None; L. Vilá, None.

To cite this abstract in AMA style:

Medina-Cintrón N, Martínez I, Pérez-Ríos N, Berríos-López Y, Vilá L. Clinical Manifestations and Outcomes in DMARD-Naïve Patients with Chronic Chikungunya Arthritis [abstract]. Arthritis Rheumatol. 2020; 72 (suppl 10). https://acrabstracts.org/abstract/clinical-manifestations-and-outcomes-in-dmard-naive-patients-with-chronic-chikungunya-arthritis/. Accessed .
  • Tweet
  • Email
  • Print

« Back to ACR Convergence 2020

ACR Meeting Abstracts - https://acrabstracts.org/abstract/clinical-manifestations-and-outcomes-in-dmard-naive-patients-with-chronic-chikungunya-arthritis/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology